IGSF22 Inhibitors
IGSF22 inhibitors are a group of chemical compounds that influence the functional activity of the protein IGSF22 through various signaling pathways and cellular processes. Staurosporine, as a kinase inhibitor, can reduce the phosphorylation status of IGSF22, which is essential for its activation and signaling efficacy. PI3K inhibitors like Ly294002 and wortmannin decrease the activity of Akt, which is an important modulator of downstream proteins including IGSF22. This results in the dampening of IGSF22's functional activity. mTOR inhibitor rapamycin has a broader impact on protein synthesis and cellular signaling, which subsequently affects IGSF22 functionality. MEK inhibitors such as PD98059 and U0126 prevent the activation of the MAPK/ERK pathway, which is often crucial for the post-translational modification of proteins like IGSF22, thereby inhibiting their function.
Furthermore, SB203580 specifically targets p38 MAP kinase, influencing the cellular response to stress and cytokines that could regulate IGSF22 activity. Src family kinases, which can be inhibited by PP2, are knownfor phosphorylating various proteins, and their inhibition could reduce IGSF22's phosphorylation and activity. SP600125's inhibition of JNK alters transcription regulation, which may impact IGSF22 function. EGFR's role in activating downstream proteins means that gefitinib's inhibition of this receptor can result in functional inhibition of IGSF22. Sorafenib, a multi-kinase inhibitor, affects the MAPK pathway by inhibiting Raf kinases, potentially leading to decreased IGSF22 activity. Lastly, imatinib, while targeting kinases not directly associated with IGSF22, can still influence its functional activity through the complex network of cellular signaling pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent nonspecific kinase inhibitor that can inhibit a wide range of protein kinases. By inhibiting protein kinases that are involved in the phosphorylation of IGSF22, staurosporine would reduce the activation and signaling efficacy of IGSF22, leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of PI3K, which is upstream of several signaling pathways, including Akt. By inhibiting PI3K, Ly294002 decreases Akt activation; since Akt can regulate a multitude of downstream proteins including IGSF22, the functional activity of IGSF22 is decreased. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor that works similarly to Ly294002, wortmannin blocks the PI3K pathway leading to a decrease in Akt-mediated signaling. Reduced PI3K activity can subsequently lead to decreased functional activity of IGSF22. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor that indirectly downregulates protein synthesis and can affect the protein levels of numerous proteins involved in cell signaling, including IGSF22. By reducing mTOR activity, the downstream effects can include decreased functional activity of IGSF22. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor that blocks the MAPK/ERK pathway. By inhibiting MEK, PD98059 would prevent the activation of ERK, which could be involved in the post-translational modification of IGSF22, thereby inhibiting its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound inhibits p38 MAP kinase. By inhibiting p38, it affects the cellular response to stress and cytokines, which could be involved in regulating IGSF22 activity. Reduced p38 activity can lead to decreased IGSF22 signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
A Src family kinase inhibitor. Src kinases can phosphorylate a variety of substrates, including proteins like IGSF22. Inhibition by PP2 could reduce IGSF22 phosphorylation and thus its functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK). JNK is implicated in the control of a number of cellular processes. Inhibition can lead to altered transcription regulation that may reduce IGSF22 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Selectively inhibits MEK1 and MEK2, similar to PD98059, leading to the inhibition of the MAPK/ERK pathway. This would reduce the phosphorylation and hence the activity of proteins modulated by this pathway, including IGSF22. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An EGFR tyrosine kinase inhibitor. By inhibiting EGFR, it prevents downstream signaling which might be crucial for the activation of proteins such as IGSF22, leading to its functional inhibition. | ||||||